This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Laxxon Medical has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Subscribe To Our Newsletter & Stay Updated
